Cargando…

Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis

PURPOSE OF REVIEW: Adalimumab is one of the top-selling drugs worldwide. Its imminent patent expiration has seen the emergence of numerous biosimilar agents. In this article, we recap the evidence from bio-originator trials in rheumatoid arthritis (RA) to provide context for a critical review of bio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhao, Sizheng, Chadwick, Laura, Mysler, Eduardo, Moots, Robert J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2018
Materias:	Biosimilars (E Mysler, Section Editor)
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6097048/ https://www.ncbi.nlm.nih.gov/pubmed/30094742 http://dx.doi.org/10.1007/s11926-018-0769-6

Ejemplares similares

Review of Biosimilar Trials and Data on Etanercept in Rheumatoid Arthritis
por: Chadwick, Laura, et al.
Publicado: (2018)

Switching Between Reference Biologics and Biosimilars for the Treatment of Rheumatology, Gastroenterology, and Dermatology Inflammatory Conditions: Considerations for the Clinician
por: Moots, Robert, et al.
Publicado: (2017)

AVT02: An Adalimumab Biosimilar
por: Kang, Connie
Publicado: (2022)

GP2015: An Etanercept Biosimilar
por: Deeks, Emma D.
Publicado: (2017)

SB8: A Bevacizumab Biosimilar
por: Syed, Yahiya Y.
Publicado: (2020)

PF-06438179/GP1111: An Infliximab Biosimilar
por: Al-Salama, Zaina T.
Publicado: (2018)

MYL-1402O: A Bevacizumab Biosimilar
por: Lee, Arnold
Publicado: (2021)

Switching from originator adalimumab to biosimilar SB5 in a rheumatology cohort: persistence on treatment, predictors of drug interruption and safety analysis
por: Bruni, Cosimo, et al.
Publicado: (2021)

The effectiveness and safety of infliximab compared with biosimilar CT‐P13, in 3112 patients with ulcerative colitis
por: Meyer, Antoine, et al.
Publicado: (2019)

Patient-reported outcomes for tofacitinib with and without methotrexate, or adalimumab with methotrexate, in rheumatoid arthritis: a phase IIIB/IV trial
por: Strand, Vibeke, et al.
Publicado: (2019)

Adalimumab Biosimilars in the Treatment of Rheumatoid Arthritis: A Systematic Review of the Evidence for Biosimilarity
por: Huizinga, Tom W. J., et al.
Publicado: (2020)

Biomarkers for Treatment Response in Rheumatoid Arthritis: Where are they?
por: Zhao, Sizheng Steven, et al.
Publicado: (2020)

Efficacy and Safety of Adalimumab Biosimilars: Current Critical Clinical Data in Rheumatoid Arthritis
por: Lu, XiaoQin, et al.
Publicado: (2021)

Real-Life Tolerability and Effectiveness of Adalimumab Biosimilar in Rheumatoid Arthritis: ASPIRE Registry Data
por: Kapoor, Sanjiv, et al.
Publicado: (2019)

Population pharmacokinetics of subcutaneous infliximab CT‐P13 in Crohn’s disease and ulcerative colitis
por: Hanzel, Jurij, et al.
Publicado: (2021)

Immunogenicity of an adalimumab biosimilar, FKB327, and its reference product in patients with rheumatoid arthritis
por: Alten, Rieke, et al.
Publicado: (2020)

Phase III Randomized Study of SB5, an Adalimumab Biosimilar, Versus Reference Adalimumab in Patients With Moderate‐to‐Severe Rheumatoid Arthritis
por: Weinblatt, Michael E., et al.
Publicado: (2017)

Population pharmacokinetics of adalimumab biosimilar adalimumab‐adbm and reference product in healthy subjects and patients with rheumatoid arthritis to assess pharmacokinetic similarity
por: Kang, Jia, et al.
Publicado: (2020)

Real‐life Tolerability and Effectiveness of Adalimumab Biosimilar in Ankylosing Spondylitis: the Adalimumab Biosimilar Patient Registry Data
por: Kapoor, Sanjiv, et al.
Publicado: (2019)

A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira®) in the treatment of active rheumatoid arthritis
por: Fleischmann, Roy M., et al.
Publicado: (2018)

Phase III trials of JAK1 selective inhibitors in rheumatoid arthritis
por: Mysler, Eduardo, et al.
Publicado: (2021)

Comparison of Efficacy and Safety of Original and Biosimilar Adalimumab in Active Rheumatoid Arthritis in a Real-World National Cohort
por: Popescu, Claudiu Costinel, et al.
Publicado: (2022)

Switching From Reference Adalimumab to SB5 (Adalimumab Biosimilar) in Patients With Rheumatoid Arthritis: Fifty‐Two–Week Phase III Randomized Study Results
por: Weinblatt, Michael E., et al.
Publicado: (2018)

Benefit–Risk Analysis of Upadacitinib Compared with Adalimumab in the Treatment of Patients with Moderate-to-Severe Rheumatoid Arthritis
por: Conaghan, Philip, et al.
Publicado: (2021)

Demonstration of Physicochemical and Functional Similarity of Biosimilar Adalimumab-aqvh to Adalimumab
por: Jiang, Yijia, et al.
Publicado: (2023)

Continuous effectiveness and safety after a hospital‐wide switch to adalimumab biosimilar: An observational study in rheumatoid arthritis patients
por: Brouwer, Rianne, et al.
Publicado: (2022)

Long-term efficacy, safety, and immunogenicity of the adalimumab biosimilar, PF-06410293, in patients with rheumatoid arthritis after switching from reference adalimumab (Humira®) or continuing biosimilar therapy: week 52–92 data from a randomized, double-blind, phase 3 trial
por: Fleischmann, Roy M., et al.
Publicado: (2021)

Development of Rheumatoid Nodules after Anti-Tumor Necrosis Factor-α Treatment with Adalimumab for Rheumatoid Arthritis
por: Shin, Sungsik, et al.
Publicado: (2016)

Correction to: AVT02: An Adalimumab Biosimilar
por: Kang, Connie
Publicado: (2022)

Navigating adalimumab biosimilars: an expert opinion
por: Abitbol, Vered, et al.
Publicado: (2023)

The switch from etanercept originator to SB4: data from a real-life experience on tolerability and persistence on treatment in joint inflammatory diseases
por: Bruni, Cosimo, et al.
Publicado: (2020)

Current and Emerging DMARDs for the Treatment of Rheumatoid Arthritis
por: Mysler, Eduardo, et al.
Publicado: (2021)

Clinical scenarios-based guide for tofacitinib in rheumatoid arthritis
por: Mortezavi, Mahta, et al.
Publicado: (2023)

Etanercept originator versus etanercept biosimilar for the treatment of rheumatoid arthritis as a first biologic: results from the BSRBR-RA
por: Kearsley-Fleet, Lianne, et al.
Publicado: (2023)

Long-term safety and efficacy of upadacitinib or adalimumab in patients with rheumatoid arthritis: results through 3 years from the SELECT-COMPARE study
por: Fleischmann, Roy, et al.
Publicado: (2022)

Cost-effectiveness of adalimumab for rheumatoid arthritis in Germany
por: Gissel, C., et al.
Publicado: (2016)

Long-term treatment of rheumatoid arthritis with adalimumab
por: Murdaca, Giuseppe, et al.
Publicado: (2013)

A Case of Isotretinoin Therapy-Refractory Folliculitis Decalvans Treated Successfully with Biosimilar Adalimumab (Exemptia)
por: Shireen, Furtado, et al.
Publicado: (2018)

Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience?
por: Mysler, Eduardo, et al.
Publicado: (2021)

Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response
por: Fleischmann, Roy M, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_3gea2cuvablmq1upi4adhsth5d